Paliperidone Palmitate
11 NDCs across 1 manufacturer|0 Generic,11 Brand
Paliperidone Palmitate is used to treat bipolar disorder, depressive disorder and schizophrenia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 31, 2009. In 2024, Medicare Part D spent $2.5 billion on Paliperidone Palmitate across 695,000 claims for 95,000 beneficiaries.
Paliperidone Palmitate is available as 11 NDCs from 1 manufacturer (0 generic, 11 brand), with NADAC prices from $2337.05 to $4233.40 per ML — a 81% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
11
0G / 11B
Manufacturers
1
competing in market
Price Spread
$2337.05 – $4233.40
per ML
7d Activity
avg -0.1% WoW · of 11 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Janssen Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Atypical Antipsychotic class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing PALIPERIDONE PALMITATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
INVEGA HAFYERA 1,560 MG/5 ML | $4233.4015 per ML | — |
INVEGA HAFYERA 1,092 MG/3.5 ML | $4047.7090 per ML | — |
INVEGA TRINZA 819 MG/2.63 ML | $3997.9706 per ML | +0.07% |
INVEGA TRINZA 546 MG/1.75 ML | $3993.6341 per ML | +0.01% |
INVEGA TRINZA 410 MG/1.32 ML | $3959.4621 per ML | -0.01% |
INVEGA TRINZA 273 MG/0.88 ML | $3950.9489 per ML | — |
INVEGA SUSTENNA 117 MG/0.75 ML | $2339.6685 per ML | -0.05% |
INVEGA SUSTENNA 39 MG/0.25 ML | $2338.7480 per ML | -0.17% |
INVEGA SUSTENNA 234 MG/1.5 ML | $2338.4746 per ML | -0.01% |
INVEGA SUSTENNA 156 MG/ML SYRG | $2337.7083 per ML | 0.00% |
INVEGA SUSTENNA 78 MG/0.5 ML | $2337.0483 per ML | -0.26% |
Frequently Asked Questions
What is Paliperidone Palmitate used to treat?
Paliperidone Palmitate is used to treat bipolar disorder, depressive disorder and schizophrenia, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Paliperidone Palmitate?
In 2024, Medicare Part D spent $2.5 billion on Paliperidone Palmitate across 695,000 claims for 95,000 beneficiaries.
How many Paliperidone Palmitate products are on the market?
The Paliperidone Palmitate drug market contains 11 NDCs from 1 manufacturer — 0 generic and 11 brand products.
What is the price range for Paliperidone Palmitate?
NADAC reference prices for Paliperidone Palmitate range from $2337.0483 to $4233.4015 per ML — a 81% difference between cheapest and most expensive.
Which manufacturers make Paliperidone Palmitate?
1 manufacturer lists Paliperidone Palmitate in NADAC. Ranked by number of NDCs, the largest are Janssen Pharmaceuticals Inc. (11).
How has the price of Paliperidone Palmitate changed recently?
Over the past 7 days, 2 Paliperidone Palmitate NDCs rose and 5 fell, with a market-wide average change of -0.1%.